Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals

AIMS: For vancomycin treatment in obese patients, there is no consensus on the optimal dose that will lead to the pharmacodynamic target (area under the curve 400–700 mg h L(−1)). This prospective study quantifies vancomycin pharmacokinetics in morbidly obese and nonobese individuals, in order to gu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Smit, Cornelis, Wasmann, Roeland E., Goulooze, Sebastiaan C., Wiezer, Marinus J., van Dongen, Eric P.A., Mouton, Johan W., Brüggemann, Roger J.M., Knibbe, Catherijne A.J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7015748/
https://ncbi.nlm.nih.gov/pubmed/31661553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14144
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars